This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
pharmaceuticals: Archive
The Zacks Analyst Blog Highlights Microsoft, Alibaba Group, Merck, Monarch Cement and Team
by Zacks Equity Research
MSFT, BABA, and MRK headline today's top analyst picks, with AI, global e-commerce, and oncology driving mixed growth stories.
MSFTPositive Net Change MRKPositive Net Change TISINegative Net Change BABAPositive Net Change MCEMNegative Net Change
business-services computers construction pharmaceuticals retail
MRK's Buyout Spree to Broaden Product Portfolio: Can it Aid Growth?
by Kanishka Das
Merck's impending Verona buyout and recent biotech deals aim to expand its pipeline and cut reliance on Keytruda sales.
SNYPositive Net Change MRKPositive Net Change LLYPositive Net Change VRNANo Net Change
pharmaceuticals
FDA Accepts GSK Filing for Expanded Use of RSV Shot in Younger Adults
by Zacks Equity Research
FDA accepts GSK's filing to extend Arexvy's RSV vaccine use to high-risk adults under 50, with a decision due in 2026.
GSKPositive Net Change PFEPositive Net Change MRNANegative Net Change
biotechs medical messenger-rna pharmaceuticals vaccines
Bayer Gets FDA Nod for Label Expansion of Kerendia in Heart Failure
by Zacks Equity Research
BAYRY wins FDA nod to expand Kerendia's label, making it the only approved non-steroidal MR antagonist for two major conditions.
NVSNegative Net Change JNJNegative Net Change BAYRYNegative Net Change
biotechnology biotechs medical pharmaceuticals
Should J&J Stock Be in Your Portfolio Ahead of Q2 Earnings?
by Kinjel Shah
JNJ eyes Q2 growth with strong drug sales and new launches, but Stelara biosimilars and MedTech headwinds loom.
JNJNegative Net Change AMGNNegative Net Change KVUEPositive Net Change
pharmaceuticals
Top Analyst Reports for Microsoft, Alibaba & Merck
by Mark Vickery
MSFT, BABA, and MRK lead today's top analyst picks, with AI, e-commerce, and cancer drug strategies in sharp focus.
MSFTPositive Net Change MRKPositive Net Change IBKRPositive Net Change BCENegative Net Change MPCPositive Net Change TISINegative Net Change BABAPositive Net Change MCEMNegative Net Change
business-services computers construction pharmaceuticals retail
FDA Accepts Merck's Filing for Two-Drug, Once-Daily HIV Pill
by Zacks Equity Research
MRK's regulatory filing for once-daily HIV pill DOR/ISL gets FDA acceptance, with a decision expected by April 2026.
MRKPositive Net Change ALKSNegative Net Change GILDNegative Net Change AMRNPositive Net Change
pharmaceuticals
MRUS Stock Soars 30% in 3 Months After Phase II Cancer Study Success
by Zacks Equity Research
Merus jumps 30% in three months after its cancer combo therapy showed significant efficacy in a phase II head and neck squamous cell carcinoma study.
MRKPositive Net Change BAYRYNegative Net Change MRUSPositive Net Change VRNANo Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
Bayer Wins Hormone-Free Treatment Approval for Women in the UK
by Zacks Equity Research
BAYRY secures first global approval for Lynkuet in the UK, a hormone-free treatment for menopause-related hot flashes.
NVSNegative Net Change JNJNegative Net Change BAYRYNegative Net Change
biotechnology biotechs medical pharmaceuticals
ABBV or BMY: Which Biopharma Giant Has Better Prospects for Now?
by Ekta Bagri
AbbVie edges ahead of Bristol Myers with strong Skyrizi and Rinvoq growth, offsetting Humira declines and portfolio headwinds.
BMYPositive Net Change ABBVPositive Net Change
biotechnology biotechs medical pharmaceuticals
Smart Money Going in Senior Health: Key Stocks in Elderly Care
by Urmimala Biswas
RHHBY, NVO, EW and SYK are ramping up senior care innovation as aging populations reshape global healthcare demand.
ABTNegative Net Change RHHBYPositive Net Change NVOPositive Net Change MDTPositive Net Change SYKNegative Net Change EWNegative Net Change
healthcare medical medical-devices pharmaceuticals
Can Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?
by Sundeep Ganoria
LLY rides high on surging demand for Mounjaro and Zepbound, now nearly half its revenues ahead of Q2 earnings.
NVOPositive Net Change LLYPositive Net Change VKTXNegative Net Change
biotechs medical pharmaceuticals
TEVA Stock Up More than 20% in Three Months: Buy, Sell or Hold the Stock?
by Kinjel Shah
TEVA stock jumps 21.6% in three months on branded drug growth, biosimilar launches, and margin-boosting cost cuts.
SNYPositive Net Change JNJNegative Net Change AMGNNegative Net Change TEVAPositive Net Change
pharmaceuticals
Merck's VRNA Buyout to Add Novel COPD Therapy: How to Play the Stock?
by Kinjel Shah
MRK's $10B buyout of VRNA brings in Ohtuvayre, a unique COPD therapy set to bolster its cardio-pulmonary portfolio.
MRKPositive Net Change MRNANegative Net Change SMMTNegative Net Change VRNANo Net Change
pharmaceuticals
RARE, MREO Fall as Osteogenesis Study Likely to Continue Till Year End
by Zacks Equity Research
Ultragenyx Pharmaceutical and Mereo BioPharma shares tumble as investors await key phase III UX143 osteogenesis data now set for release at year-end.
BAYRYNegative Net Change RARENegative Net Change VRNANo Net Change MREOPositive Net Change
biotechnology biotechs medical pharmaceuticals
Lilly Down More Than 15% in a Year: Time to Buy, Sell or Hold?
by Kinjel Shah
LLY has slid 15.7% over the past year, but surging demand for Mounjaro and Zepbound could revive the stock's momentum.
NVOPositive Net Change LLYPositive Net Change AMGNNegative Net Change VKTXNegative Net Change
pharmaceuticals
Pharma Companies Remain Calm Amid Fresh Tariff Threat by Trump
by Ekta Bagri
Trump revives tariff threats on pharma imports, but industry giants like LLY and JNJ stay unfazed with major U.S. investments underway.
NVSNegative Net Change RHHBYPositive Net Change JNJNegative Net Change LLYPositive Net Change
biotechnology biotechs medical pharmaceuticals
Best Value Stocks to Buy for July 10th
by Zacks Equity Research
BAYRY, INSW and GOOS made it to the Zacks Rank #1 (Strong Buy) value stocks list on July 10, 2025.
BAYRYNegative Net Change GOOSNegative Net Change INSWNegative Net Change
pharmaceuticals retail transportation
The Zacks Analyst Blog Highlights SAP SE, Novo Nordisk, Thermo Fisher Scientific and FONAR
by Zacks Equity Research
SAP, NVO, TMO and FONR navigate growth and headwinds as analysts spotlight cloud momentum, obesity drugs, and innovation plays.
NVOPositive Net Change TMONegative Net Change SAPPositive Net Change FONRNegative Net Change
pharmaceuticals
New Strong Buy Stocks for July 10th
by Zacks Equity Research
ASTH, LGCY, STM, BAYRY and KD have been added to the Zacks Rank #1 (Strong Buy) List on July 10, 2025.
STMNegative Net Change BAYRYNegative Net Change LGCYNegative Net Change KDNegative Net Change ASTHPositive Net Change
business-services consumer-discretionary medical pharmaceuticals semiconductor
Top Research Reports for SAP, Novo Nordisk & Thermo Fisher
by Mark Vickery
SAP gains on cloud strength, NVO faces obesity setbacks, and TMO leans on AI and innovation amid macro headwinds.
NVOPositive Net Change TMONegative Net Change SAPPositive Net Change PSXPositive Net Change CGNegative Net Change HUBSPositive Net Change HURCNegative Net Change FONRNegative Net Change
computers industrial-products medical medical-devices pharmaceuticals
RXRX Stock Up on Acquiring Full Rights to the Hypophosphatasia Program
by Zacks Equity Research
Recursion Pharmaceuticals stock jumps after securing full rights to REV102, aiming to fast-track the first oral therapy for hypophosphatasia.
BAYRYNegative Net Change VRNANo Net Change RXRXPositive Net Change RLYBNegative Net Change
biotechnology biotechs medical pharmaceuticals
Is Novo Nordisk Increasing Dosage to Defend Wegovy's Edge in Obesity?
by Ahan Chakraborty
NVO submits higher-dose Wegovy to EMA, aiming for greater weight loss and stronger defense against rivals in the obesity market.
NVOPositive Net Change LLYPositive Net Change VKTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
Merck Faces Multiple Challenges: Will It Steer Through Successfully?
by Kanishka Das
MRK banks on new launches as Keytruda faces a looming patent cliff and Gardasil weakens amid China's demand slump.
JNJNegative Net Change PFEPositive Net Change MRKPositive Net Change LLYPositive Net Change
pharmaceuticals
Will Recent Label Expansions of Opdivo Help BMY Gain Momentum?
by Zacks Equity Research
BMY leans on Opdivo's solid growth and new approvals as generics pressure its other top drugs and shares remain under pressure.
RHHBYPositive Net Change BMYPositive Net Change MRKPositive Net Change
biotechnology biotechs medical pharmaceuticals